Download these slides from a live CCO Webinar for an overview of the latest clinical data informing optimal use of ALK, ROS1, RET, NTRK, KRAS G12C, and METex14 biomarkers to guide therapeutic decisions in advanced NSCLC, including updates from recent annual clinical oncology meetings.
Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC
Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)
From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress
In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.